Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -157.13M | -158.10M | -164.08M | -120.74M | -122.27M |
| Total Depreciation and Amortization | 693.00K | 751.00K | 1.03M | 1.17M | 1.97M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -11.50M | -9.47M | -8.45M | -44.78M | -50.44M |
| Change in Net Operating Assets | -65.85M | -36.94M | -37.02M | -25.40M | -14.17M |
| Cash from Operations | -233.79M | -203.76M | -208.51M | -189.74M | -184.91M |
| Capital Expenditure | -941.00K | -884.00K | -868.00K | -612.00K | -1.16M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -843.46M | -394.79M | -329.00K | 59.26M | 200.80M |
| Cash from Investing | -844.40M | -395.68M | -1.20M | 58.65M | 199.63M |
| Total Debt Issued | 287.55M | 273.97M | 180.85M | 142.59M | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.58M | 4.91M | 866.00K | 539.00K | 314.00K |
| Repurchase of Common Stock | -- | -- | -- | 0.00 | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 781.34M | 431.23M | -1.15M | -1.15M | 0.00 |
| Cash from Financing | 1.07B | 710.11M | 180.57M | 141.98M | 314.00K |
| Foreign Exchange rate Adjustments | 1.00K | 7.00K | 6.00K | 39.00K | 10.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.72M | 110.68M | -29.14M | 10.92M | 15.05M |